Loading quotes...
Forecast
The analysts' average price target is €0.23 (+163.46%). The median is €0.23 (+163.46%).
| Buy |
5 |
| Hold |
5 |
| Sell |
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Applied Therapeutics delisted from Nasdaq after takeover by Cycle Group
Applied Therapeutics has completed its merger with Cycle Group Holdings and is now an indirect wholly owned subsidiary of Cycle Group. Cycle Group subsidiary AT2B acquired all outstanding shares for $0.088 per share; shareholders also received a non-tradable CVR with potential payments of up to $0.40. Applied filed to suspend trading, delist and deregister with the SEC; the board and several executives resigned, and James Harrison took over leadership. Cycle is integrating the lead drug candidate Govorestat into its portfolio; analysts sharply cut ratings and price targets for Applied stock following the transaction. » More on de.investing.com
Cycle extends takeover offer for Applied Therapeutics
Cycle Group Holdings has extended the deadline for its takeover offer for Applied Therapeutics to 11:59 p.m. ET on January 29, 2026. Cycle is offering $0.088 per share in cash plus a non-tradable contingent value right; the price is close to the stock’s 52-week low. The board of directors of Applied Therapeutics unanimously recommends tendering the shares and warns that, if tendering is insufficient, liquidation and the immediate repayment of an $8.5 million promissory note to Cycle would likely follow. Financial data show a weak financial picture with negative EBITDA and significant financial challenges for Applied Therapeutics. » More on de.investing.com
Applied Therapeutics explores strategic alternatives and cuts 46% of workforce
Applied Therapeutics has launched a process to evaluate strategic options such as M&A, partnerships and licensing agreements to maximize shareholder value. At the same time, the company is reducing costs by cutting 46% of its workforce; it did not disclose exact employee numbers. The stock fell sharply last year and the company reported a negative EBITDA of USD 99.61 million, but says it has more cash than debt. Applied Therapeutics is reviewing FDA Type C meeting minutes for its lead candidate govorestat and considering next steps, after also agreeing a $75 million share sale facility with Cantor Fitzgerald. » More on de.investing.com
Applied Therapeutics stock plunges after uncertainty in FDA approval process for Govorestat
Applied Therapeutics shares fell about 55% in pre-market trading after the company said the next steps for a Govorestat approval filing, including a potential accelerated submission, have not been determined. Applied is waiting for the official FDA meeting minutes to decide how to proceed; it had previously aimed for a submission in Q3 2025. Govorestat is being developed to treat the rare neuropathy CMT‑SORD and already has multiple regulatory special designations in the US and Europe. » More on de.investing.com
FDA discussion on Govorestat sends Applied Therapeutics stock sharply higher
Applied Therapeutics completed a meeting with the FDA about a potential regulatory filing for Govorestat to treat CMT‑SORD. The stock jumped sharply after investors learned of the discussion; the company is now waiting for the official meeting minutes before determining next steps. Govorestat has orphan drug status from the FDA and EMA and is also being developed for other rare diseases. Applied Therapeutics has also entered an agreement for an at‑the‑market equity offering of up to USD 75 million to raise capital. » More on de.investing.com
Financials
| (EUR) | September 2025 | YoY |
|---|---|---|
| Revenue | 852.13K | - |
| Gross profit | 852.13K | - |
| Net profit | -16.18M | - |
| EBITDA | -16.09M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €13.5M |
Number of shares | 144.3M |
52-week high/low | €1.36 - €0.0818 |
| Dividends | No |
Beta | 2.08 |
P/E ratio | -0.37 |
PEG ratio | 0.00 |
P/B ratio | -26.72 |
P/S ratio | 14.86 |
Company profile
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
| Name | Applied Therapeutics |
| CEO | Les D. Funtleyder |
| Headquarters | New York City,
ny USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 05/14/2019 |
| Employees | 35 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | APLT |
Frankfurt | 2UV.F |
Düsseldorf | 2UV.DU |
München | 2UV.MU |